Immunocore Holdings plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMCR research report →
Companywww.immunocore.com
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.
- CEO
- Bahija Jallal
- IPO
- 2021
- Employees
- 493
- HQ
- Abingdon, GB
Price Chart
Valuation
- Market Cap
- $1.50B
- P/E
- -79.66
- P/S
- 3.89
- P/B
- 3.81
- EV/EBITDA
- -526.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.81%
- Op Margin
- -7.61%
- Net Margin
- -4.88%
- ROE
- -4.83%
- ROIC
- -3.52%
Growth & Income
- Revenue
- $297.57M · 20.00%
- Net Income
- $-26,418,662 · 35.26%
- EPS
- $-0.53 · 48.04%
- Op Income
- $-33,737,839
- FCF YoY
- -153.61%
Performance & Tape
- 52W High
- $40.72
- 52W Low
- $27.55
- 50D MA
- $30.13
- 200D MA
- $33.14
- Beta
- 0.74
- Avg Volume
- 381.55K
Get TickerSpark's AI analysis on IMCR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 17, 26 | Coy Travis Alan | other | 95,637 |
| Feb 17, 26 | Coy Travis Alan | other | 33,353 |
| Feb 17, 26 | Jallal Bahija | other | 395,066 |
| Feb 17, 26 | Jallal Bahija | other | 88,573 |
| Feb 17, 26 | Jallal Bahija | other | 23,817 |
| Feb 17, 26 | Jallal Bahija | other | 23,817 |
| Feb 18, 26 | Jallal Bahija | sell | 11,474 |
| Feb 17, 26 | GOLL JOHN | other | 21,252 |
| Feb 17, 26 | GOLL JOHN | other | 7,411 |
| Feb 17, 26 | GOLL JOHN | other | 1,351 |
Our IMCR Coverage
We haven't published any research on IMCR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMCR Report →